Skip to main content
Fig. 6 | Molecular Neurodegeneration

Fig. 6

From: A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model

Fig. 6

Barnes maze testing of WT and PS19 mice treated with vehicle or 51657. The vehicle-treated PS19 mice had a modest deficit relative to vehicle-treated WT mice in successfully identify the escape compartment in the maze during the first two days of testing, and the PS19 mice receiving 51657 showed a non-significant trend toward improvement on day 1 and 2 compared to the vehicle group. Because of the modest amount of tau pathology and absence of overt neuron loss in the 12-month female PS19 mice, the behavioral deficits were mild and all treatment groups showed nearly 100% performance by the third and fourth days of testing

Back to article page